BioMedica can fill the hole

Oxford BioMedica, the gene therapy group that came to the market mid-December, and was caught up in the mini-crash on Wall Street, and a hideous market for new issues, will this week decide whether to pursue legal action against the two underwriters which pulled out of the deal. The move left BioMedica with a pounds 1m hole in its fund raising efforts. The deal still managed to get off the runway, but from the offer price of 88p, it dived to 47p. However, chief executive Alan Kingsman says the company is comfortable with its financial position, and has recruited three senior staff to boost its research efforts. An announcement next month will confirm details of a scientific advisory panel. Based on its research, and the quality of its staff, the shares, at 57.5p, still merit a buy.

CIRQUAL, the aluminium extrusions business, tipped here at 152.5p in September, is now sitting pretty at 191.5p. As expected, in December the company became the first AIM company to transfer to a full listing on the main market, and for its maiden figures, beat its prospectus forecast, posting pre-tax profits of pounds 2.96m. The shares have been further boosted by an upbeat AGM statement last week by its chairman, former FKI chief, Tony Gartland. Yet the shares still trade at a prospective multiple of 11 times, if profits hit pounds 5.3m this year, which should be possible. Buy.

BACK on the biotechnology beat, Stanford Rook (525.5p) announced interesting findings last week for its M. vaccae treatment, in a pilot study on patients suffering from or skin cancer. The company said 25 per cent of a 36 strong patient group showed improved antibody response, required for immunity to cancer. The market was clearly aware of the pending news, as the shares were up 90p to 522p before the news was released. However there is little in the findings to offer any concrete evidence of long term benefits. The trial did not have a control group of any description, and there are still doubters about the company's research. Avoid.

SILVERMINES (81.5p), the Irish-based group with an expanding presence in closed-circuit television, has exited the last of its non-electronics businesses with the IRpounds 2.6m disposal of its Shannon Business Park. It has also won a major CCTV contract in Asia with the China Construction Bank. The group should beat analysts' forecasts of pounds 4.1m for the year to December 30, 1996. Buy.

TINY Rowland issued another string of questions for Lonrho (127.5p), ahead of its full-year results last Thursday. Unsurprisingly, there were no answers. But his point about Anglo American's sugar business, Tongaat- Huelett's, interest in Lonrho's sugar estates, is correct. Anglo wants the Lonrho sugar business - and Lonrho may be willing to part with an excellent operation. However, there are difficulties here, even if the two sides do reach agreement on price. Lonrho's sugar business has protected status for sales of its sugar cane into the UK, where it can sell at above the world price. This may not hold true for Anglo. The two businesses, however, know each other well, and would make a good fit. But even if there were a deal, it would not resolve the problems at Lonrho, and the shares are best avoided.

Suggested Topics
Start your day with The Independent, sign up for daily news emails
Arts and Entertainment
Lou Reed distorted the truth about his upbringing, and since his death in 2013, biographers and memoirists have added to the myths
musicThe truth about Lou Reed's upbringing beyond the biographers' and memoirists' myths
News
people
News
Ed Miliband received a warm welcome in Chester
election 2015
Life and Style
Apple CEO Tim Cook announces the Apple Watch during an Apple special even
fashionIs the Apple Watch for you? Well, it depends if you want it for the fitness tech, or for the style
ebooks
ebooksA special investigation by Andy McSmith
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + OTE £45,000: SThree: SThree Group have been well e...

Ashdown Group: IT Manager / Development Manager - NW London - £58k + 15% bonus

£50000 - £667000 per annum + excellent benefits : Ashdown Group: IT Manager / ...

Recruitment Genius: Sales Consultant / Telemarketer - OTE £20,000

£13000 - £20000 per annum: Recruitment Genius: Scotland's leading life insuran...

Ashdown Group: Training Programme Manager - City, London

£40000 - £45000 per annum + benefits : Ashdown Group: Training Programme Manag...

Day In a Page

Armenian genocide: To continue to deny the truth of this mass human cruelty is close to a criminal lie

Armenian genocide and the 'good Turks'

To continue to deny the truth of this mass human cruelty is close to a criminal lie
Lou Reed: The truth about the singer's upbringing beyond the biographers' and memoirists' myths

'Lou needed care, but what he got was ECT'

The truth about the singer's upbringing beyond
Migrant boat disaster: This human tragedy has been brewing for four years and EU states can't say they were not warned

This human tragedy has been brewing for years

EU states can't say they were not warned
Women's sportswear: From tackling a marathon to a jog in the park, the right kit can help

Women's sportswear

From tackling a marathon to a jog in the park, the right kit can help
Hillary Clinton's outfits will be as important as her policies in her presidential bid

Clinton's clothes

Like it or not, her outfits will be as important as her policies
NHS struggling to monitor the safety and efficacy of its services outsourced to private providers

Who's monitoring the outsourced NHS services?

A report finds that private firms are not being properly assessed for their quality of care
Zac Goldsmith: 'I'll trigger a by-election over Heathrow'

Zac Goldsmith: 'I'll trigger a by-election over Heathrow'

The Tory MP said he did not want to stand again unless his party's manifesto ruled out a third runway. But he's doing so. Watch this space
How do Greek voters feel about Syriza's backtracking on its anti-austerity pledge?

How do Greeks feel about Syriza?

Five voters from different backgrounds tell us what they expect from Syriza's charismatic leader Alexis Tsipras
From Iraq to Libya and Syria: The wars that come back to haunt us

The wars that come back to haunt us

David Cameron should not escape blame for his role in conflicts that are still raging, argues Patrick Cockburn
Sam Baker and Lauren Laverne: Too busy to surf? Head to The Pool

Too busy to surf? Head to The Pool

A new website is trying to declutter the internet to help busy women. Holly Williams meets the founders
Heston Blumenthal to cook up a spice odyssey for British astronaut manning the International Space Station

UK's Major Tum to blast off on a spice odyssey

Nothing but the best for British astronaut as chef Heston Blumenthal cooks up his rations
John Harrison's 'longitude' clock sets new record - 300 years on

‘Longitude’ clock sets new record - 300 years on

Greenwich horologists celebrate as it keeps to within a second of real time over a 100-day test
Fears in the US of being outgunned in the vital propaganda wars by Russia, China - and even Isis - have prompted a rethink on overseas broadcasters

Let the propaganda wars begin - again

'Accurate, objective, comprehensive': that was Voice of America's creed, but now its masters want it to promote US policy, reports Rupert Cornwell
Why Japan's incredible long-distance runners will never win the London Marathon

Japan's incredible long-distance runners

Every year, Japanese long-distance runners post some of the world's fastest times – yet, come next weekend, not a single elite competitor from the country will be at the London Marathon
Why does Tom Drury remain the greatest writer you've never heard of?

Tom Drury: The quiet American

His debut was considered one of the finest novels of the past 50 years, and he is every bit the equal of his contemporaries, Jonathan Franzen, Dave Eggers and David Foster Wallace